Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 104

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1A
Chunk 104
---
 and changes in governmental or private insurer reimbursement levels for our tests, including UnitedHealthcare's decision to no longer provide coverage for certain multi-gene panel genetic tests, including our GeneSight test, under its commercial, individual exchange, and certain managed Medicaid plans;

•introduction of new commercial tests or technological innovations by competitors;

•termination of the licenses underlying our tests;

•delays or other problems with operating our laboratory facilities;

•failure of any of our research and development programs, including the failure to achieve favorable results from our clinical studies or receive sufficient favorable exposure for our tests in peer-reviewed publications;

•changes in intellectual property laws or the enforcement, validity or expiration of our patents in the United States and foreign countries;

•developments or disputes concerning patents or other proprietary rights involving us directly or otherwise affecting the industry as a whole;

•missing or changing the financial guidance we provide;

•failure of analysts to initiate or maintain coverage of our company; 

•negative publicity, including misinformation, about our company, our tests or the industry in which we operate;

•changes in the government regulatory approval process for our existing and new tests;

•failure to meet estimates or recommendations by securities analysts that cover our common stock;

•issuance of new securities analysts reports or changes in estimates or recommendations by securities analysts relating to our common stock or the securities of our competitors;

•general perception of, and public concern over the industry and our approved tests and any test candidates;

•litigation, including the outcome of existing and new litigation against us;

•government and regulatory investigations;

•our ability to raise additional funds if and when needed;

•future sales or anticipated sales of our common stock by us or our stockholders;

•the timing and amount of any repurchases of our common stock;

•general market conditions, including as a result of changes in the rate of inflation and interest rates;

•potential seasonal slowness in sales, particularly in the quarters ending September 30 and March 31, the effects of which may be difficult to understand during periods of growth;

•economic, health care and diagnostic trends, disasters or crises and other external factors; and

•period-to-period fluctuations in our financial results.

These and other external factors may cause the market price and demand for our common stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of common stock and may otherwise negatively affect the liquidity of our common stock.

55

Table of Contents

If we are unable to achieve and maintain effective disclosure controls and procedures and internal